Jalal A Aram

6PUBLICATIONS
20CO-AUTHORS
Molecular targetsForest health and pathologyMedical bacteriologyMedical infection agents (incl. prions)Innate immunity
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (6)

|Apr 06, 2026
Exploring Early Antifungal Activity of Rezafungin as a Stepping-Stone for Shorter Treatment Duration for Candidemia: Pooled Analysis of 2 Randomized Trials.

Luis Ostrosky-Zeichner, Jalal A Aram, Mark Redell

|Feb 25, 2025
Antifungal Policy and Practice Across Five Countries: A Qualitative Review.

David W Denning, John R Perfect, Neda Milevska-Kostova

|Mar 25, 2024
Outcomes by Candida spp. in the ReSTORE Phase 3 trial of rezafungin versus caspofungin for candidemia and/or invasive candidiasis.

Jeffrey B Locke, Chris M Pillar, Mariana Castanheira

|May 15, 2023
Post-hoc analysis of the safety and efficacy of isavuconazole in older patients with invasive fungal disease from the VITAL and SECURE studies.

Kamal Hamed, Marc Engelhardt, Laura L Kovanda

|Jun 10, 2022
Effectiveness and safety of isavuconazole prophylaxis for invasive fungal infections in the haematologic setting.

Yang Ping, Jing Hongmei, Christian Bellmann

|Dec 28, 2020
Clinical experience with isavuconazole in healthy volunteers and patients with invasive aspergillosis in China, and the results from an exposure-response analysis.

Jing Zhang, Yingyuan Zhang, Depei Wu

Pageof 1

Frequent Collaborators

2 joint publications

Kamal Hamed

2 joint publications

Oliver A Cornely

1 joint publications

Tom Macmillan

1 joint publications

Olaf Penack